Mitigation of therapeutic anti‐CD38 antibody interference with fab fragments: How well does it perform?
Sign Up to like & getrecommendations! Published in 2023 at "Transfusion"
DOI: 10.1111/trf.17253
Abstract: Administration of anti‐CD38 antibodies is a state‐of‐the‐art therapy for patients diagnosed with multiple myeloma (MM). However, this treatment frequently leads to pan‐agglutination of red blood cells (RBCs) in patients' serological testing making accurate blood typing… read more here.
Keywords: anti cd38; cd38 antibody; interference fab; antibody interference ... See more keywords
Abstract 2266: SAR442085, a next generation anti-CD38 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) against multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Immunology"
DOI: 10.1158/1538-7445.am2020-2266
Abstract: CD38 is a cell surface glycoprotein highly expressed in multiple myeloma (MM) cells making it an attractive target for antibody–based therapy. Anti–CD38 treatment represents a major breakthrough in the treatment of relapsing and refractory multiple… read more here.
Keywords: antibody; cd38 antibody; cd38; sar442085 ... See more keywords